You can buy or sell DOVA and other stocks, options, ETFs, and crypto commission-free!
Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Read More Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.
Durham, North Carolina
52 Week High
52 Week Low
Simply Wall StMar 8
Dova Pharmaceuticals, Inc.’s (NASDAQ:DOVA) Profit Outlook
Dova Pharmaceuticals, Inc.’s (NASDAQ:DOVA): Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. On 31 December 2018, the US$210m market-cap posted a loss of -US$72.3m for its most recent financial year. As path to profitability is the topic on DOVA’s investors mind, I’ve decided to gauge market sentiment. Below I will provide a high-level summary of the industry analysts’ expectations for DOVA. View our la...
Yahoo FinanceMar 7
Is the Options Market Predicting a Spike in Dova (DOVA) Stock?
Investors in Dova Pharmaceuticals, Inc. DOVA need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $2.50 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It ...
The Motley FoolMar 5
Dova Pharmaceuticals, Inc. (DOVA) Q4 2018 Earnings Conference Call Transcript
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Q4 2018 Earnings Conference Call , 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon and welcome to Dova Pharmaceutical's Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights Conference Call. All lines have been placed on mute to prevent any background noise. Following the speakers' remarks, there will be a question-and-answer session. Before we begin, I would li...
Expected May 8, Pre-Market